Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRMT5 | O14744 | 1/20 | 0.40 |
| ▸ | WDR77 | Q9BQA1 | 1/20 | 0.40 |
| ▸ | DAO | P14920 | 1/20 | 0.38 |
| ▸ | MKNK1 | Q9BUB5 | 1/20 | 0.35 |
| ▸ | MKNK2 | Q9HBH9 | 1/20 | 0.35 |
| ▸ | PRKAB2 | O43741 | 1/20 | 0.34 |
| ▸ | PRKAG1 | P54619 | 1/20 | 0.34 |
| ▸ | PRKAA2 | P54646 | 1/20 | 0.34 |
| ▸ | PRKAA1 | Q13131 | 1/20 | 0.34 |
| ▸ | PRKAG3 | Q9UGI9 | 1/20 | 0.34 |
| ▸ | PRKAG2 | Q9UGJ0 | 1/20 | 0.34 |
| ▸ | PRKAB1 | Q9Y478 | 1/20 | 0.34 |
| ▸ | HCAR2 | Q8TDS4 | 3/20 | 0.34 |
| ▸ | HCAR3 | P49019 | 1/20 | 0.32 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.30 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.30 |
| ▸ | PIK3C3 | Q8NEB9 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29327043 | 1.00 | PRMT5 (0.40) | PRMT5WDR77DAOMKNK1MKNK2 | |
| SCHEMBL31080297 | 0.90 | HCAR2 (0.37) | PRMT5WDR77MKNK1MKNK2HCAR2 | |
| SCHEMBL4016705 | 0.89 | DAO (0.47) | PRMT5WDR77DAOMKNK1MKNK2 | |
| SCHEMBL14722873 | 0.85 | MKNK1 (0.35) | MKNK1MKNK2HCAR2HCAR3PDPK1 | |
| SCHEMBL18403239 | 0.79 | DAO (0.38) | PRMT5WDR77DAOPRKAB2PRKAG1 | |
| SCHEMBL15882695 | 0.79 | DAO (0.38) | PRMT5WDR77DAOPRKAB2PRKAG1 | |
| SCHEMBL56939 | 0.79 | — | — | |
| Hydrochloric Acid SCHEMBL17107724 | 0.77 | HCAR2 (0.48) | DAOMKNK1MKNK2HCAR2HCAR3 | |
| SCHEMBL3551909 | 0.76 | HCAR2 (0.49) | DAOMKNK1MKNK2HCAR2HCAR3 | |
| SCHEMBL1269829 | 0.76 | HCAR2 (0.53) | DAOMKNK1MKNK2HCAR2HCAR3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4695238-A1 | CDK2 INHIBITORS | Blueprint Medicines Corporation (US) | 2026-02-18 | — | — | EP | disclosed |
| EP-4646414-A1 | CDK2 INHIBITORS | Blueprint Medicines Corporation (US) | 2025-11-12 | — | — | EP | disclosed |
| WO-2024216154-A1 | CDK2 INHIBITORS | BLUEPRINT MEDICINES CORPORATION (US) | 2024-10-17 | — | — | WO | disclosed |
| WO-2024148091-A1 | CDK2 INHIBITORS | BLUEPRINT MEDICINES CORPORATION (US) | 2024-07-11 | — | — | WO | disclosed |
| WO-2024148091-A1 | CDK2 INHIBITORS | BLUEPRINT MEDICINES CORPORATION (US) | 2024-07-11 | — | — | WO | disclosed |
| WO-2022174253-A1 | HPK1 ANTAGONISTS AND USES THEREOF | Nimbus Saturn, Inc. (US) | 2022-08-18 | — | — | WO | disclosed |
| EP-3927699-A1 | MODULATORS OF MYC FAMILY PROTO-ONCOGENE PROTEIN | Nalo Therapeutics (US) | 2021-12-29 | — | — | EP | disclosed |
| US-10028942-B2 | 3-substituted pyrazoles and uses thereof | GENENTECH, INC. (US) | 2018-07-24 | — | — | US | disclosed |
| US-10028942-B2 | 3-substituted pyrazoles and uses thereof | GENENTECH, INC. (US) | 2018-07-24 | — | — | US | disclosed |
| US-10028942-B2 | 3-substituted pyrazoles and uses thereof | GENENTECH, INC. (US) | 2018-07-24 | — | — | US | disclosed |
| US-20160002228-A1 | 3-SUBSTITUTED PYRAZOLES AND USE AS DLK INHIBITORS | GENENTECH, INC. (US) | 2016-01-07 | — | — | US | disclosed |
| US-20160002228-A1 | 3-SUBSTITUTED PYRAZOLES AND USE AS DLK INHIBITORS | GENENTECH, INC. (US) | 2016-01-07 | — | — | US | disclosed |
| US-20160002228-A1 | 3-SUBSTITUTED PYRAZOLES AND USE AS DLK INHIBITORS | GENENTECH, INC. (US) | 2016-01-07 | — | — | US | disclosed |
| EP-2945938-A1 | 3-SUBSTITUTED PYRAZOLES AND USE AS DLK INHIBITORS | F. Hoffmann-La Roche AG (CH) | 2015-11-25 | — | — | EP | disclosed |
| WO-2014111496-A1 | 3-SUBSTITUTED PYRAZOLES AND USE AS DLK INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2014-07-24 | — | — | WO | disclosed |
| WO-2014111496-A1 | 3-SUBSTITUTED PYRAZOLES AND USE AS DLK INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2014-07-24 | — | — | WO | disclosed |
| EP-2748159-A1 | SERINE/THREONINE PAK1 INHIBITORS | F.HOFFMANN-LA ROCHE AG (CH) | 2014-07-02 | — | — | EP | disclosed |
| US-8637537-B2 | Serine/threonine kinase inhibitors | GENENTECH, INC. (US) | 2014-01-28 | — | — | US | disclosed |
| US-20130225620-A1 | SERINE/THREONINE KINASE INHIBITORS | GENENTECH, INC. (US) | 2013-08-29 | — | — | US | disclosed |
| WO-2013026914-A1 | SERINE/THREONINE PAK1 INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2013-02-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160002228-A1 | 3-SUBSTITUTED PYRAZOLES AND USE AS DLK INHIBITORS | PDXK, NLK, PDK3 | PRMT5 47/4885WDR77 462/4885DAO 1320/4885 |
| US-20130225620-A1 | SERINE/THREONINE KINASE INHIBITORS | PAK1, AKT1, RB1 | PRMT5 382/4885WDR77 1304/4885DAO 3974/4885 |
| US-10028942-B2 | 3-substituted pyrazoles and uses thereof | PDXK, NLK, PDK3 | PRMT5 28/4885WDR77 554/4885DAO 1228/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.